114 related articles for article (PubMed ID: 22917635)
1. Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Angelico F; Del Ben M; Pignatelli P; Violi F
Dig Liver Dis; 2013 Jan; 45(1):81-2. PubMed ID: 22917635
[No Abstract] [Full Text] [Related]
2. Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
Dig Liver Dis; 2013 Jan; 45(1):82-3. PubMed ID: 23058851
[No Abstract] [Full Text] [Related]
3. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Yamagishi S; Maeda S; Hyogo H
Dig Liver Dis; 2013 Jan; 45(1):83-4. PubMed ID: 23099228
[No Abstract] [Full Text] [Related]
4. Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Yamagishi S
Dig Liver Dis; 2013 Jan; 45(1):82. PubMed ID: 22909420
[No Abstract] [Full Text] [Related]
5. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
[TBL] [Abstract][Full Text] [Related]
6. If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?
Lonardo A; Loria P
Dig Liver Dis; 2012 Jun; 44(6):451-2. PubMed ID: 22487461
[No Abstract] [Full Text] [Related]
7. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
[TBL] [Abstract][Full Text] [Related]
10. Piriformis muscle syndrome: an unusual adverse effect of atorvastatin.
Hamdi W; Ghannouchi MM; Kaffel D; Kchir MM
J Clin Rheumatol; 2013 Apr; 19(3):156-7. PubMed ID: 23519180
[No Abstract] [Full Text] [Related]
11. [Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA].
Mareev VIu; Belenkov IuN; Oganov RG; Barbik-Zhagar B
Kardiologiia; 2008; 48(11):4-13. PubMed ID: 19076074
[No Abstract] [Full Text] [Related]
12. A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
Lee CW; Baek SH; Hong TJ; Choi YJ; Kim YJ; Ahn TH; Ihm SH; Bae JH; Hong SJ; Kim DI; Ahn YK; Hur SH; Park DG; Choi DJ; Lee SU; Kim BS; Ryu KH; Jang YS; Lee SH; Seung KB; Kim HS
Cardiovasc Drugs Ther; 2010 Apr; 24(2):181-8. PubMed ID: 20383571
[TBL] [Abstract][Full Text] [Related]
13. [Effective cholesterol and triglyceride lowering with atorvastatin].
Internist (Berl); 1996 Aug; 37(8 Suppl Effektive):1-8. PubMed ID: 9404527
[No Abstract] [Full Text] [Related]
14. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Kimura Y; Hyogo H; Yamagishi S; Takeuchi M; Ishitobi T; Nabeshima Y; Arihiro K; Chayama K
J Gastroenterol; 2010 Jul; 45(7):750-7. PubMed ID: 20112031
[TBL] [Abstract][Full Text] [Related]
15. More on atorvastatin and fibrinogen.
Otto C; Schwandt P
Atherosclerosis; 2000 Aug; 151(2):591-2. PubMed ID: 10944081
[No Abstract] [Full Text] [Related]
16. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Ogata N; Fujimori S; Oka Y; Kaneko K
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):321-4. PubMed ID: 20544514
[TBL] [Abstract][Full Text] [Related]
17. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
18. Aggressive LDL-cholesterol lowering with atorvastatin results in regression of atherosclerosis.
Cardiovasc J S Afr; 2001; 12(1):56. PubMed ID: 11474689
[No Abstract] [Full Text] [Related]
19. Lipid-lowering with atorvastatin improves tissue characteristics of carotid plaque.
Katakami N; Sakamoto K; Kaneto H; Matsuhisa M; Hori M; Yamasaki Y; Kosugi K; Waki H
Atherosclerosis; 2005 Dec; 183(2):369-71. PubMed ID: 16162349
[No Abstract] [Full Text] [Related]
20. [Medical management of primary nonalcoholic fatty liver disease].
Moreno Sánchez D
Med Clin (Barc); 2005 Jun; 125(3):108-16. PubMed ID: 15989845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
